Medpace (MEDP) falls after Q1 revenue beat as drug development services peers edge higher

Medpace shares have fallen 16.6% to $413.94 after the clinical research services company reported Q1 revenue of $706.6 million, up 26.5% from a year earlier and 1.5% above analyst estimates. The company also beat EPS expectations, while full-year EPS guidance was in line with consensus. Across eight tracked drug development inputs and services companies, Q1 revenue exceeded analyst estimates by an average 1.6%, and shares are up 1.3% on average since results were released, according to the report published May 14, 2026. West Pharmaceutical Services (WST) posted the strongest revenue beat, with sales of $844.9 million, up 21% and 8.4% above estimates; its stock rose 16.6% to $320. Azenta (AZTA) missed revenue and EPS estimates, sending shares down 26.6% to $18.06. Repligen (RGEN) rose 14.8% in revenue to $194.3 million and traded flat at $118.50, while Fortrea (FTRE) rose 22.4% despite revenue falling 2.3%.